Persistent Cancer Cells: The Deadly Survivors

被引:184
|
作者
Shen, Shensi [1 ]
Vagner, Stephan [3 ,4 ,5 ]
Robert, Caroline [1 ,2 ,6 ]
机构
[1] Gustave Roussy Canc Campus, INSERM U981, Villejuif, France
[2] Univ Paris Sud, Univ Paris Saclay, Le Kremlin Bicetre, France
[3] PSL Res Univ, Inst Curie, INSERM U1278, CNRS,UMR3348, Orsay, France
[4] Univ Paris Sud, Univ Paris Saclay, INSERM U1278, CNRS,UMR3348, Orsay, France
[5] Equipe Labellisee Ligue Natl Canc, Orsay, France
[6] Gustave Roussy Canc Campus, Dermatooncol, Villejuif, France
关键词
STRESS-INDUCED MUTAGENESIS; FATTY-ACID OXIDATION; MESENCHYMAL TRANSITION; METABOLIC SYMBIOSIS; TARGETED THERAPY; PROSTATE-CANCER; TUMOR DORMANCY; LUNG-CANCER; RESISTANCE; MELANOMA;
D O I
10.1016/j.cell.2020.10.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug treatment and constitute a major cause of treatment failure. These cells are characterized by their slow proliferation, highly flexible energy consumption, adaptation to their microenvironment, and phenotypic plasticity. Mechanisms that underlie their persistence offer highly coveted and sought-after therapeutic targets, and include diverse epigenetic, transcriptional, and translational regulatory processes, as well as complex cell-cell interactions. Although the successful clinical targeting of persistent cancer cells remains to be realized, immense progress has been made in understanding their persistence, yielding promising preclinical results.
引用
收藏
页码:860 / 874
页数:15
相关论文
共 50 条
  • [31] The experience of persistent pain in adult cancer survivors: A qualitative evidence synthesis
    Armoogum, Julie
    McCabe, Candy
    Harcourt, Diana
    Foster, Claire
    Llewellyn, Alison
    PSYCHO-ONCOLOGY, 2019, 28 : 14 - 14
  • [32] Predictive factors for persistent and late radiation complications in breast cancer survivors
    Fekrmandi, F.
    Panzarella, T.
    Dinniwell, R. E.
    Helou, J.
    Levin, W.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 360 - 369
  • [33] Predicting Persistent Opioid Use, Abuse, and Toxicity Among Cancer Survivors
    Vitzthum, Lucas K.
    Riviere, Paul
    Sheridan, Paige
    Nalawade, Vinit
    Deka, Rishi
    Furnish, Timothy
    Mell, Loren K.
    Rose, Brent
    Wallace, Mark
    Murphy, James D.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (07): : 720 - 727
  • [34] T-cell homeostasis in breast cancer survivors with persistent fatigue
    Bower, JE
    Ganz, PA
    Aiziz, N
    Fahey, JL
    Cole, SW
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (15): : 1165 - 1168
  • [35] Predicting Persistent Opioid Use, Abuse and Toxicity Among Cancer Survivors
    Vitzthum, L.
    Riviere, P.
    Sheridan, P.
    Nalawade, V.
    Deka, R.
    Xu, R.
    Mell, L. K.
    Wallace, M.
    Murphy, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S71 - S71
  • [36] Effect of persistent menopausal symptoms on the wellbeing of Japanese breast cancer survivors
    Yamamoto, Sena
    Masutani, Eiko
    Arao, Harue
    NURSING & HEALTH SCIENCES, 2016, 18 (03) : 379 - 386
  • [37] The experience of persistent pain in adult cancer survivors: A qualitative evidence synthesis
    Armoogum, Julie
    Harcourt, Diana
    Foster, Claire
    Llewellyn, Alison
    McCabe, Candida S.
    EUROPEAN JOURNAL OF CANCER CARE, 2020, 29 (01)
  • [38] Yoga for Persistent Fatigue in Breast Cancer Survivors: Results of a Pilot Study
    Bower, Julienne E.
    Garet, Deborah
    Sternlieb, Beth
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2011, 2011 : 1 - 8
  • [39] Predictive factors for persistent and late radiation complications in breast cancer survivors
    F. Fekrmandi
    T. Panzarella
    R. E. Dinniwell
    J. Helou
    W. Levin
    Clinical and Translational Oncology, 2020, 22 : 360 - 369
  • [40] Diagnosis of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors
    Freites-Martinez, Azael
    Shapiro, Jerry
    JAMA DERMATOLOGY, 2022, 158 (06) : 704 - 704